A to Z of CV Pharmacotherapy | Inclisiran: A Jab Goes a Long Way

Watch on Radcliffe Cardiology: www.radcliffecardiology.com/w...
High levels of low-density lipoprotein (LDL) cholesterol can increase the risk of atherosclerosis and cardiovascular events such as a heart attack or stroke. Inclisiran, now approved by NICE (2021) can be used to reduce LDL cholesterol.
Do you know when, how and on which patients to use the novel anti-cholesterol drug inclisiran to treat elevated LDL in patients with hypercholesterolaemia, mixed dyslipidaemia or patients that have had a previous cardiovascular event?
Join our webinar and learn more during an interactive panel discussion, showcasing real-world case applications of this new agent, produced as part of the ISCP series on the A to Z of CV Pharmacotherapy.
Led by moderators Dr Krittin Bunditakanul (Bangkok, Thailand) and Dr Doreen Tan (Singapore), it includes a speaker presentation from Prof Kyzysztof Filipiak (Warsaw, Poland), two case presentations from Dr Bundaitakanul and discussions from panellists Prof Bernard Cheung (Hong Kong) and Dr Alberto Lorenzatti (Argentina) that will examine the considerations for use of this new agent, through interesting real-world examples, live discussions and audience Q&A.
This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.
Reserve your seat for the next webinar in the series and view on-demand today!
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

[@truthhurts1446]

Informative, great to hear experts from many corners of the world 😊